Disease Landscape and Forecast Insights

What Are Physician and Payer Expectations as New Mechanisms of Action Transform the Market Landscape? Significant opportunity remains for therapies to treat moderate to severe ulcerative colitis…

LaunchTrends: Anoro Ellipta Wave 2 is the second of a three-wave report series designed to track the postlaunch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment…

How Are Payers Responding to High-Cost Therapies on Their Exchange-Based Plans? The Affordable Care Act (ACA) has expanded access to insurance coverage to millions and has reformed health…

In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus erythematosus (SLE) and the first drug approved for SLE in more than 50 years. However,…

Last Updated 29 December 2014 Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of it represents a large untapped market owing to…

Diabetes is a chronic, progressive metabolic disease in which the body lacks or is resistant to endogenous insulin, leading to a state of persistent high blood sugar (referred to as hyperglycemia…

LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant…

LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant…

Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once…

This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the…

Historically, developers of systemic lupus erythematosus (SLE) drugs faced formidable challenges: drug development and regulatory hurdles, a small and heterogeneous population, and a multiplicity…

ChartTrends®: Psoriasis 2014 (US) provides insight into the management and treatment of psoriasis patients by dermatologists based on actual patient-level data. More than 180 U.S. dermatologists…